Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diabetes mellitus (type 1 or 2) (for the patients) or absence of diabetes mellitus and other carbohydrates metabolism alterations (for the non diabetic controls)~* Age 20-65 years;~* Both genders;~* Informed consent.~Exclusion criteria:~* Age \<20 or \>65 years;~* Pregnancy or lactation \*~* Recent surgery or trauma;~* Recent acute diseases (within 2 months from study entry);~* Immune diseases (except from type I diabetes and autoimmune thyroiditis);~* Chronic infectious diseases;~* Hematologic malignancies either past or present;~* Solid tumor known or strongly suspected;~* Leukocytosis, leukopenia, or thrombocytopenia;~* Solid organ transplant or immunosuppression;~* Alteration of hepatic function (transaminases \>2 ULN);~* Severe chronic diabetic micro- or macroangiopathy~* HbA1c \>11%.~* Deficit in renal function (eGFR\<50 ml/m2);~* Significant abnormalities of the peripheral lymphocyte immunophenotype;~* Known hypersensitivity to Mozobil or its excipients;~* Refusal / inability to provide informed consent.~  * women with childbearing potential can participate to this trial just if are using effective oral contraception; a negative pregnancy test is required before study entry). Women will be asked to continue oral contraception for 3 months after Mozobil administration.~All antidiabetic medications are allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Stem cell mobilization in diabetic patients (Type: EXPERIMENTAL): Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
- Stem cell mobilization in non diabetic subjects (Type: EXPERIMENTAL): Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).